CiVi Biopharma
Kevin joined CiVi Biopharma in May 2018 as vice president, operations and planning. He has more than 15 years of experience in the pharmaceutical industry, most recently as the president and chief operating officer of Eicos Sciences, a wholly-owned subsidiary of CiVi Biopharma.
Previously, Kevin spent 12 years at Actelion Pharmaceuticals, where he held various commercial leadership positions and led a number of highly successful product launches. Prior to Actelion, he was a healthcare consultant at ZS Associates and Putnam Associates.
This person is not in any offices
CiVi Biopharma
CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.